IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3390
Positioning
Market Dominance
Finance, Insurance, And Real Estate
Trading
$399M
Bradley J. Muth
Transcontinental Realty Investors, Inc., a Dallas-based real estate investment company, holds a diverse portfolio of equity real estate. The Company invests in real estate through direct ownership, leases and partnerships.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = TCI ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$SII SPROTT INC. | 75 | 91 | 87 | 98 | - | - | 15.7% | 12.8% | 48.9% | 37.0% | 28.8% | 14.9% | 2.5% | 0.0x | $1.1B | VS | |
$PUK PRUDENTIAL PLC | 73 | 88 | 97 | 80 | - | - | 13.2% | 1.4% | 100.0% | 97.0% | 23.8% | 11.8% | 2.7% | 5.0x | $21.5B | VS | |
$NMR NOMURA HOLDINGS INC | 72 | 81 | 92 | 87 | - | - | 9.9% | 0.6% | 84.5% | 70.0% | 7.3% | 14.9% | 0.0% | 923.0x | $18.3B | VS | |
$PSLV Sprott Physical Silver Trust | 69 | 82 | 80 | 98 | - | - | 17.3% | 17.7% | 100.0% | 100.0% | 100.0% | 1643.8% | 0.0% | 0.0x | $5.0B | VS | |
$UFCS UNITED FIRE GROUP INC | 68 | 81 | 93 | 76 | 5.0x | 3.5x | 13.2% | 4.1% | 99.9% | 14.7% | 11.1% | 9.2% | 2.1% | 16.0x | $775M | VS | |
$SLF SUN LIFE FINANCIAL INC | 68 | 83 | 95 | 63 | - | - | 12.6% | 0.9% | 32.0% | 31.3% | 7.9% | -12.9% | 4.3% | 24.0x | $37.8B | VS | |
$CBOE Cboe Global Markets, Inc. | 68 | 75 | 63 | 77 | 21.3x | 15.7x | 24.0% | 13.7% | 41.7% | 32.4% | 26.4% | 8.2% | 1.1% | 30.0x | $25.7B | VS | |
$PHYS Sprott Physical Gold Trust | 67 | 64 | 82 | 91 | - | - | 22.5% | 22.8% | 101.8% | 100.0% | 100.0% | 138.9% | 0.0% | 0.0x | $8.4B | VS | |
$VTMX Vesta Real Estate Corporation, S.A.B. de C.V. | 67 | 69 | 77 | 80 | - | - | 8.8% | 5.8% | 98.7% | 75.7% | 88.5% | 17.6% | 4.3% | 34.0x | $2.2B | VS | |
$GLDM World Gold Trust | 66 | 54 | 85 | 92 | 11.3x | 11.3x | - | 27.1% | 100.0% | 98.9% | 459.9% | 333.4% | 0.0% | 0.0x | $43.7B | VS | |
$TCI TRANSCONTINENTAL REALTY INVESTORS INC | 41 | 32 | 23 | 60 | 49.7x | 64.2x | 0.9% | 0.7% | 41.0% | -9.3% | 16.5% | 9.0% | 0.0% | 26.0x | $399M | ||
| SECTOR BENCH | - | - | - | - | - | 11.9x | 7.8x | 8.9% | 1.2% | 76.5% | 17.0% | 21.5% | 10.8% | 1.9% | 0.5x | - | REF |
TRANSCONTINENTAL REALTY INVESTORS INC (TCI) receives a "Reduce" rating with a composite score of 41.2/100. It ranks #3390 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Bradley J. Muth
Chief Executive Officer
32
30
39
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for TCI
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Finance, Insurance, And Real Estate sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for TCI.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 32 | 51 | -19DRAG |
| MOMENTUM | 60 | 66 | -6DRAG |
| VALUATION | 23 | 7 | +16ALPHA |
| INVESTMENT | 30 | 39 | -9DRAG |
| STABILITY | 39 | 33 | +6ALPHA |
| SHORT INT | 47 | 48 | -1NEUTRAL |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC -0.5% vs WACC 6.4% (spread -6.9%)
GM 41% vs sector 77%, OM -9% vs sector 17%
Capital turnover 0.06x
Rev growth 9%, 10yr history
Interest coverage -0.8x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
TRANSCONTINENTAL REALTY INVESTORS INC receives a Reduce rating from our analysis, with a composite score of 41.2/100 and 2 out of 5 stars, ranking #3390 out of 7,333 stocks. TCI's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
TCI's quality score of 32/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of 0.9% (sector avg: 8.9%), gross margins of 41.0% (sector avg: 76.5%), net margins of 16.5% (sector avg: 21.5%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
TCI registers a value score of just 23/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/E ratio of 49.66x, an EV/EBITDA of 64.16x, a P/B ratio of 0.46x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
TRANSCONTINENTAL REALTY INVESTORS INC's investment score of 30/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 9.0% vs. a sector average of 10.8% and a return on assets of 0.7% (sector: 1.2%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
TCI demonstrates moderate momentum with a score of 60/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 9.0% year-over-year, while a beta of 0.57 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
TCI's stability score of 39/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.57 and a debt-to-equity ratio of 26.00x (sector avg: 0.5x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 47/100 for TCI suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 26.00x), small-cap liquidity risk. With a $399M market cap (small-cap), TRANSCONTINENTAL REALTY INVESTORS INC may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
TRANSCONTINENTAL REALTY INVESTORS INC is a small-cap company in the Finance, Insurance, And Real Estate sector, ranked #0 of 50 in its sector (100th percentile) and #3390 of 7,333 overall (54th percentile). Key comparisons include ROE of 0.9% trailing the 8.9% sector median and operating margins of -9.3% below the 17.0% sector average. This top-quartile standing reflects exceptional competitive strength relative to Finance, Insurance, And Real Estate peers.
While TCI currently exhibits a REDUCE profile, superior opportunities exist within the FINANCE, INSURANCE, AND REAL ESTATE sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Finance, Insurance, And Real Estate Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (23) would have the largest impact on the composite score.
EV/EBITDA 726% ABOVE SECTOR MEDIAN
ROE 90% BELOW SECTOR MEDIAN
Gross Margin 46% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate TRANSCONTINENTAL REALTY INVESTORS INC (TCI) as a Reduce with a composite score of 41.2/100 at a current price of $41.76. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in momentum (60th percentile) and stability (39th percentile), which together account for the majority of the composite score. Offsetting weakness in value (23th percentile) and investment (30th percentile) tempers our overall conviction. We assign a No Moat rating (17/100), Low uncertainty, and Standard capital allocation.
Key items to watch: valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
TRANSCONTINENTAL REALTY INVESTORS INC holds a top-quartile position (#0 of 50) within the Finance, Insurance, And Real Estate sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 41.2/100 places it at rank #3390 in our full 7,333-stock universe. At $399M in market capitalization, TRANSCONTINENTAL REALTY INVESTORS INC is a small-cap player in the Finance, Insurance, And Real Estate space, which limits certain scale advantages but may allow for more agile strategic execution.
The outlook is moderately positive, with revenue expanding at 9% and favorable momentum (60th percentile) reflecting constructive market sentiment. The business shows steady execution, though the growth rate is below the levels typically associated with high-conviction growth stories. Momentum confirmation provides support for the current price level.
The margin cascade tells an important story: gross margins of 41% (-35.5pp vs sector) narrow to operating margins of -9% (-26.4pp vs sector) and net margins of 16.5%, yielding a gross-to-net conversion rate of 40%. This efficient conversion suggests well-controlled operating costs and limited margin leakage between the gross and net levels.
At a current price of $41.76, TRANSCONTINENTAL REALTY INVESTORS INC is trading at a premium to fundamental value. Our value factor score of 23/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at a P/E of 49.7x (a 316% premium to the sector median of 11.9x), EV/EBITDA of 64.2x (at a premium), P/B of 0.5x, P/S of 8.1x. The above-sector P/E multiple suggests the market is pricing in superior growth or quality, which our analysis finds only partially justified by current fundamentals.
Gross margins of 41% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
A conservative balance sheet (26% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Reduce rating (composite 41.2/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
A P/E of 49.7x leaves little room for execution misses — any earnings disappointment could trigger a sharp multiple compression.
Below-average quality (32th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a Low uncertainty rating to TRANSCONTINENTAL REALTY INVESTORS INC. The company exhibits strong financial stability with a beta of 0.57, conservative leverage (26% D/E), and a stability factor in the 39th percentile. The predictable nature of the business model and solid financial position reduce the range of potential outcomes, giving us confidence in our fair value estimate.
Specific risk factors that inform our assessment include: below-average price stability (39th percentile); weak quality scores (32th percentile); low beta of 0.57 — while defensive, this may indicate limited upside participation in bull markets; elevated valuation multiple (P/E 49.7x) that leaves limited margin for error. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 39th percentile and quality factor at the 32th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 41% provide a buffer against cost pressures; conservative leverage (26% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate TRANSCONTINENTAL REALTY INVESTORS INC's capital allocation as Standard. Management has shown adequate — though not exceptional — stewardship of shareholder capital. Returns on equity stand at 0.9%, and the balance sheet is managed within acceptable parameters (D/E: 26%). Exemplary allocators typically sustain ROE above 20% and D/E below 50%; TRANSCONTINENTAL REALTY INVESTORS INC falls short on at least one dimension.
There is room for improvement in optimizing the capital structure or enhancing shareholder returns. Absent a dividend, the overall capital allocation framework would benefit from either higher reinvestment returns, improved balance sheet efficiency, or increased shareholder distributions. We will monitor for signs of strategic improvement that could warrant an upgrade.
In summary, TRANSCONTINENTAL REALTY INVESTORS INC receives a Reduce rating with a composite score of 41.2/100 (rank #3390 of 7,333). Our quantitative framework assigns a No Moat (17/100, trend: stable), Low uncertainty, and Standard capital allocation. The average factor score across quality, value, momentum, stability, and investment is 37/100.
Our analysis does not support a constructive view on TRANSCONTINENTAL REALTY INVESTORS INC at this time. The combination of limited competitive advantages, low uncertainty, and standard capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign TRANSCONTINENTAL REALTY INVESTORS INC a meaningful economic moat, scoring 17/100 on our composite assessment. The ROIC-WACC spread of -6.9% is the primary signal of economic value creation. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, financial resilience, reached only 7.5/20.
The strongest moat sources are financial resilience (7.5/20) and growth durability (4.9/20). Interest coverage -0.8x. Rev growth 9%, 10yr history. These pillars form the core of TRANSCONTINENTAL REALTY INVESTORS INC's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and economic value creation (1.2/20). Capital turnover 0.06x. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect TRANSCONTINENTAL REALTY INVESTORS INC's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 41% providing a solid profitability foundation, moderate revenue growth of 9%. The margin cascade from 41% gross to -9% operating to 16.5% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 32th percentile.
The margin profile shows gross margins of 41%, operating margins of -9%, net margins of 16.5%. Return metrics include ROE of 0.9% and ROA of 0.7%. Relative to the Finance, Insurance, And Real Estate sector, gross margins are 35.5 percentage points below the sector median of 77%, and ROE of 0.9% compares to a sector median of 8.9%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 26%, revenue growth of 9%. The sector median D/E is 0%, putting TRANSCONTINENTAL REALTY INVESTORS INC at higher leverage than the typical peer. The combination of low leverage and healthy profitability provides significant financial resilience and strategic optionality.
Above 50MA
37.18%
Net New Highs
+51081

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces Procurement Of 1.4M Additional Doses Of COVID-19 Pill By U.S. Merck & Co., Inc. (NYSE: MRK) said its pending acquisition of Acceleron Pharma, Inc. (NASDAQ: XLRN) has been cleared by the competition authorities in Germany and Austria. The cash tender offer Merck has commenced to purchase all outstanding shares of common stock of Acceleron, for $180 per share in cash will expire at 5 p.m. on Nov. 18. The acquisition is expected to close in the fourth quarter. Separately, Merck and Ridgeback Biotherapeutics announced the U.S. government will exercise two of its options to purchase a total of 1.4 million additional courses of molnupiravir, an investigational oral antiviral medicine, if the medicine is granted emergency use authorization or approval by the U.S. Food and Drug Administration, for approximately $1 billion. With these exercised options, the U.S. has now committed to purchase a total of approximately 3.1 million courses of molnupiravir, for approximately $2.2 billion, between authorization and early 2022. The U.S. government also has the ability to purchase more than 2 million additional courses through further options that remain in the contract. Merck shares were up 1.29% at $83.75 in premarket trading. Alkermes Receives Partial Termination Notices For Licensing Agreement With Janssen Over Technology Uses In Latter's Antipsychotic Drugs Alkermes plc (NASDAQ: ALKS) announced that it received notices of partial termination of two license agreements with Johnson & Johnson (NYSE: JNJ)'s Janssen unit. The terminations impact know-how royalties related to sales of long-acting paliperidone products, such as Invega Sustenna and Invega Trinza in the U.S. Even as Janssen maintained that it does not utilize Alkermes' "NanoCrystal" technology licensed under the agreements, Alkermes said it strongly disagrees with Janssen's position. The latter also said it will explore all options at its disposal to enforce its contractual rights and address any unauthorized use of its intellectual property. Alkermes shares were receding 7.94% to $27 in premarket trading. Related Link: The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Amgen Migraine Treatment Found Superior To Standard-Of-Care In Phase 4 Study Amgen, Inc. (NASDAQ: AMGN) announced new data from the a head-to-head Phase 4 study of Aimovig, a CGRP inhibitor, against topiramate for adult patients with episodic and chronic migraine. Topiramate is one of the most commonly prescribed medications in migraine prevention. The study conducted by Novartis AG (NYSE: NVS) showed that patients in the ...

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out to be negative for several others engaged in COVID-19 vaccine and treatment research. Pfizer announced Friday its oral COVID-19 pill Paxlovid reduced the risk of COVID-19-related hospitalization or death by 89%. Merck & Co., Inc. (MRK: NYSE), which also has a competing medication in the pipeline, shed close to 10% on Friday. Stocks also reacted to the earnings, which came in thick and fast during the week. Five stocks belonging to the biotech and diagnostics spaces, debuted on Wall Street during the week. Here are the key upcoming catalysts that biotech investors are on in the unfolding week: Health Care Conferences: American College of Rheumatology, or ACR, Convergence 2021: Nov. 3-9 (virtual) BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in Oncology: Nov. 8 (virtual event) Credit Suisse 30th Annual Virtual Healthcare Conference: Nov. 8-11 (virtual conference) 14th Clinical Trial On Alzheimer's Disease, or CTAD, 2021: Nov. 9-12 (in Boston) 6th Respiratory Syncytial Virus Network, or RESVINET, Conference: Nov. 10-12 (virtual meeting) Society For Immunotherapy of Cancer: Nov. 10-14 (hybrid event, to be held in Washington, D.C. and to be available virtually) Connective Tissue Oncology Society, or CTOS, 2021 Annual Meeting: Nov. 10-13 (virtual meeting) American Academy of Ophthalmology, or AAO, 2021 Meeting: Nov. 12-13 (in New Orleans) American Association for the Study of Liver Diseases, AASLD, The Liver Meeting 2021: Nov. 12-15 (virtual meeting) Clinical Readouts/Presentations Liver Meeting Presentations Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA): Phase 1b data for EDP-514 in viremic, chronic hepatitis B infected patients Vir Biotechnology, Inc. (NASDAQ: VIR): Preliminary results from a Phase 1 study evaluating a single dose of VIR-3434, a novel neutralizing, vaccinal monoclonal antibody, for hepatitis B infection (Friday, at 8 a.m.) Vaccitech plc (NASDAQ: VACC): Interim results of HBV001, a Phase 1 study evaluating therapeutic vaccination with ChAdOx1-HBV in healthy volunteers and patients with chronic hepatitis B infection; Phase 1b/2a study of heterologous ChAdOx1/MVA therapeutic vaccination combined with Bristol-Myers Squibb Company's (NYSE: BMY) low-dose Opdivo in virally-suppressed patients with CHB under nucleos(t)ide analogues Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA): results of a subpopulation pharmacokinetic and safety analysis from the Phase 1 trial of RG6346, which Dicerna is developing in collaboration with Roche Holding AG (OTC: RHHBY) for the treatment of chronic hepatitis B virus infection; interim Phase 1 data from Belcesiran in Alpha 1-antitrypsin deficiency-associated liver disease Lipocine Inc. (NASDAQ: LPCN): safety And tolerability Of LPCN 1144 treatment In biopsy confirmed NASH subjects from the Phase 2 LiFT study Arbutus Biopharma Corporation (NASDAQ: ABUS): data on the effects of its ...
As the U.S. market grapples with geopolitical tensions and fluctuating bond yields, small-cap stocks in the S&P 600 have shown resilience amid broader market volatility. With major indices like the Dow Jones and Nasdaq experiencing declines due to tariff threats, investors are increasingly turning their attention to lesser-known opportunities that may offer growth potential in uncertain times. In this context, identifying a good stock often involves looking for companies with strong...

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 200 points on Thursday. The Dow traded up 0.67% to 32,412.36 while the NASDAQ rose 0.39% to 12,079.66. The S&P also rose, gaining, 0.59% to 4,047.22. Also check this: Bitcoin Drops Further To This Level, Here Are Other Crypto Movers That Should Be On Your Radar Leading and Lagging Sectors Real estate shares rose 2.9% on Thursday. Meanwhile, top gainers in the sector included Equinix, Inc. (NASDAQ: EQIX), up 8% and Transcontinental Realty Investors, Inc. (NYSE: TCI) up 6%. In trading on Thursday, communication services shares fell 1.5%. Top Headline The US economy shrank an annualized 0.9% on quarter during the second quarter, compared to a 1.6% decline in the first quarter. Equities Trading UP JAKKS Pacific, Inc. (NASDAQ: JAKK) shares shot up 35% to $23.00 after the company reported better-than-expected Q2 results. Shares of ToughBuilt Industries, Inc. (NASDAQ: TBLT) got a boost, shooting 32% to $6.05 after the company entered into an agreement with Ace Hardware USA to sell 35 products across 5,500 stores. SKYX ...

Gainers BM Technologies, Inc. (NYSE: BMTX) shares climbed 26.4% to close at $11.82 on Tuesday after the company reported record Q1 results. Ultralife Corporation (NASDAQ: ULBI) jumped 23.4% to close at $10.50 on Tuesday after the company announced it was awarded an IDIQ contract under the US Army's $1.25 billion conformal wearable battery program. The company will receive no more than $168 million over a 3 year base period. Obalon Therapeutics, Inc. (NASDAQ: OBLN) surged 22% to settle at $2.88. Moxian, Inc. (NASDAQ: MOXC) gained 21% to close at $13.53. Aemetis, Inc. (NASDAQ: AMTX) jumped 20.9% to close at $12.30. Park City Group, Inc. (NASDAQ: PCYG) climbed 20.7% to close at $6.17 on Tuesday after reporting Q3 results. Agenus Inc. (NASDAQ: AGEN) shares gained 20.6% to close at $3.93 on Tuesday. Bristol-Myers Squibb Co and Agenus entered into a global exclusive license agreement, under which Bristol Myers will receive an exclusive license to Agenus' AGEN1777 and a second undisclosed target. Agrify Corporation (NASDAQ: AGFY) gained 20.5% to settle at $9.18. Agrify posted its first-quarter earnings results Monday, reporting revenue of $7 million, compared to $4.4 million and $1 million in the previous quarter and the same quarter of 2020, respectively. Virios Therapeutics, Inc. (NASDAQ: VIRI) rose 20.4% to close at $5.67 as traders circulated an article from Zacks titled 'Initiating Coverage Of Virios Therapeutics; Attacking The Root Cause Of Chronic Disease.' Inotiv, Inc. (NASDAQ: NOTV) jumped 20.2% to close at $25.25 after dropping 9% on Monday. Lordstown Motors Corp. (NASDAQ: RIDE) gained 20.1% to settle at $10.09. Lordstown Motors shares gained around 15% on Monday after the company set the dates for its "Lordstown Week" event. Orbital Energy Group, Inc. (NASDAQ: OEG) surged 19.5% to close at $3.55, rebounding after the stock dipped on Monday following worse-than-expected Q1 EPS and sales results. China HGS Real Estate Inc. (NASDAQ: HGSH) surged 18.4% to settle at $2.19 after the company reported a sharp rise in 1H sales. Aterian, Inc. (NASDAQ: ATER) jumped 18.2% to close at $16.20. Aterian recently reported a Q1 loss of $3.15 per share. NN, Inc. (NASDAQ: NNBR) jumped 18% to settle at $9.37. NN recently added Rajeev Gautam as a Director. Vor Biopharma Inc. (NASDAQ: VOR) gained 17.8% ...Full story available on Benzinga.com